Pemazyre Tablet
FDA Label NDC 50881-026

35 label sections · Submitted to the FDA by Incyte Corporation · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Incyte Corporation for the product Pemazyre (NDC 50881-026). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 cholangiocarcinoma, 1.2 myeloid/lymphoid neoplasms with fgfr1 rearrangement, 2.1 patient selection, 2.2 recommended dosage, 2.3 dosage modification for adverse reactions, 2.4 dosage modification for concomitant use with strong or moderate cyp3a inhibitors, 2.5 recommended dosage for severe renal impairment, 2.6 recommended dosage for severe hepatic impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.